Interview: Mike Harsh on the evolution of Imaging and Imagion’s role
With over 40 years’ experience in the health care diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Finfeed‘s Jonathan Jackson sat down with a very enthusiastic Harsh to discuss the industry, the limited ways to image the human body (X-ray, CT, MRI, ultrasound, and PET/SPECT) and how Imagion is reimagining the process.
Read the interview.
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
August 11, 2023
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion